Peter E. Schmid
Impact in
- Cancer Research top 0.05%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
Papers in
- Cancer Research 142
- Breast Cancer Treatment Studies 139
- Oncology 111
- Cancer Immunotherapy and Biomarkers 61
- HER2/EGFR in Cancer Research 21
- Cancer Treatment and Pharmacology 14
- Co-authors
- Hope S. Rugo (31 shared papers)Sherene Loi (32 shared papers)Hiroji Iwata (18 shared papers)Eric P. Winer (19 shared papers)Carlos H. Barrios (15 shared papers)Sylvia Adams (12 shared papers)Leisha A. Emens (11 shared papers)Luciana Lorena Molinero (9 shared papers)
- Journals
- Annals of Oncology (65 papers)Journal of Clinical Oncology (16 papers)New England Journal of Medicine (10 papers)Medicine & Science in Sports & Exercise (9 papers)ESMO Open (9 papers)
- Partner nations
- United KingdomGermanyUnited States
In The Last Decade
Peter E. Schmid
348 papers receiving 28.5k citations
Peter E. Schmid's Hit Papers
Peers
Comparison fields: 5 of 164
- Cancer Research 9.8k
- Oncology 11.4k
- Pulmonary and Respiratory Medicine 3.9k
- Biological Psychiatry 79
- Radiology, Nuclear Medicine and Imaging 1.3k
Countries citing papers authored by Peter E. Schmid
This map shows the geographic impact of Peter E. Schmid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter E. Schmid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter E. Schmid more than expected).
Fields of papers citing papers by Peter E. Schmid
This network shows the impact of papers produced by Peter E. Schmid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter E. Schmid. The network helps show where Peter E. Schmid may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter E. Schmid, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 378 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer Hit paper breakdown → | 2018 | 3493 |
| 2 | Pembrolizumab for Early Triple-Negative Breast Cancer Hit paper breakdown → | 2020 | 2318 |
| 3 | Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer Hit paper breakdown → | 2022 | 1933 |
| 4 | Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial Hit paper breakdown → | 2020 | 1393 |
| 5 | Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer Hit paper breakdown → | 2021 | 1222 |
| 6 | ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer Hit paper breakdown → | 2021 | 1015 |
| 7 | Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2019 | 975 |
| 8 | Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer Hit paper breakdown → | 2022 | 818 |
| 9 | Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer Hit paper breakdown → | 2018 | 663 |
| 10 | Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study Hit paper breakdown → | 2018 | 540 |
| 11 | Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study Hit paper breakdown → | 2018 | 498 |
| 12 | Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer Hit paper breakdown → | 2018 | 401 |
| 13 | Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2021 | 387 |
| 14 | 2013 | 352 | |
| 15 | Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial Hit paper breakdown → | 2019 | 330 |
| 16 | Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study Hit paper breakdown → | 2020 | 327 |
| 17 | Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial Hit paper breakdown → | 2023 | 322 |
| 18 | 1995 | 280 | |
| 19 | Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer Hit paper breakdown → | 2024 | 277 |
| 20 | 2016 | 260 |
About Peter E. Schmid
Peter E. Schmid is a scholar working on Cancer Research, Oncology, Pulmonary and Respiratory Medicine, Complementary and alternative medicine and Cardiology and Cardiovascular Medicine, having authored 378 papers that have together received 29.3k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (139 papers), Cancer Immunotherapy and Biomarkers (61 papers), Advanced Breast Cancer Therapies (46 papers), Cardiovascular and exercise physiology (24 papers), HER2/EGFR in Cancer Research (21 papers), Freshwater macroinvertebrate diversity and ecology (20 papers), Cancer Treatment and Pharmacology (14 papers) and Gestational Trophoblastic Disease Studies (9 papers). The work is most often cited by research in Cancer Research (9.8k citations), Oncology (11.4k citations), Pulmonary and Respiratory Medicine (3.9k citations), Biological Psychiatry (79 citations) and Radiology, Nuclear Medicine and Imaging (1.3k citations). Peter E. Schmid has collaborated with scholars based in United Kingdom, Germany and United States. Frequent co-authors include Hope S. Rugo, Sherene Loi, Hiroji Iwata, Eric P. Winer, Carlos H. Barrios, Sylvia Adams, Leisha A. Emens, Luciana Lorena Molinero, Veronique C Dieras and Seock‐Ah Im. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, New England Journal of Medicine, Medicine & Science in Sports & Exercise and ESMO Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.